Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

Summary

The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration (wAMD) to evaluate their potential in supporting the choice of treatment regimen (q12w or q8w).

Timeline

Start

2021-10-15

Primary completion

2023-10-04

Completion

2023-10-04

Publications

• Lupidi M, Bandello F, Vujosevic S, Parravano M, Bacherini D, Minnella AM, Giansanti F, Ascardi C, Staurenghi G. Multimodal Imaging to Assess Disease Activity and Predict Fluid Resolution in Patients with wAMD Treated with Brolucizumab: The IMAGINE Study. Ophthalmol Ther. 2025 Oct;14(10):2497-2510. doi: 10.1007/s40123-025-01229-5. Epub 2025 Aug 20.

Drugs

Indications